Zurück zur Übersicht
| American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2019 Jul 31. doi: 10.1111/ajt.15551 |
| Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. |
| Iavarone M1, Invernizzi F2, Czauderna C3, Sanduzzi-Zamparelli M4, Bhoori S5, Amaddeo G6, Manini MA7, Fraile López M8, Anders M9, Pinter M10, Blanco Rodríguez MJ11, Romero Cristóbal M12, Aballay Soteras G13, Piñero F14, Villadsen GE15, Weinmann A16, Crespo G17, Mazzaferro V18, Regnault H19, De Giorgio M20, González-Diéguez ML21, Donato MF22, Varela M23, Wörns MA24, Bruix J25, Lampertico P26, Reig M27 |
 Author information
|
|
Abstract Regorafenib is one option for second-line treatment of hepatocellular carcinoma (HCC), improving overall survival (OS) of sorafenib-tolerant patients who develop progression. We aim to evaluate safety and outcomes of regorafenib as second-line treatment for HCC-recurrence after liver transplantation (LT). This is a retrospective, multicentre, international study including regorafenib-treated LT-patients (2015-2018), with analysis of baseline characteristics and evolutionary-events during sorafenib/regorafenib treatment. Twenty-eight LT patients (57 years, 7% cirrhotics, 54% performance-status 1) were included. Median time from LT to regorafenib initiation was 3.9 (1.1-18.5) years; median time on sorafenib was 11.3 (0.7-76.4) months and 14 (1-591) days from sorafenib discontinuation to regorafenib. During regorafenib (6.3 months), all patients had at least 1 adverse event (AE), the most common grade 3/4 AEs were fatigue (n= 7) and dermatological reaction (n= 5). While no liver rejection was observed, plasma levels of immunosuppressive-drugs increased in 5. Twenty-four patients developed progression (38% extra-hepatic growth, 33% new extra-hepatic lesions/vascular invasion). Median OS from regorafenib initiation was 12.9 (95%CI:6.7-19.1) and 38.4 months (95%CI:18.5-58.4) for the sorafenib initiation. This is the first study showing safety of regorafenib after LT, thus providing the rational of considering regorafenib in the clinical decision-making in sorafenib-tolerant patients with HCC-recurrence after LT. This article is protected by copyright. All rights reserved. |
|
This article is protected by copyright. All rights reserved. |
|
Publikations ID: 31365177 Quelle: öffnen |
Author information
Schnellinfo
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
